The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference

Pharmacogenomics. 2016;17(1):74-9. doi: 10.2217/pgs.15.152. Epub 2015 Dec 14.

Abstract

β-ARs are extensively spread in different tissues of our body, which could be activated by neurotransmitters norepinephrine and epinephrine to mediate physiological function and abnormal states including cancer. Recently, β-AR blockers could have significant implications in cancer therapy. But the precise molecular mechanisms are far from being fully understood. Through identifying the β-AR system signal pathways relevant to cancer, we can understand the mechanisms of β-blockers used for cancer treatment. What's more, retrospective clinical data made β-blockers jump out of the traditional field of cardiovascular disease and strengthened our confidence in cancer therapy. At last, genetic studies of β-adrenergic system offered crucial genes to analyze the effects of polymorphisms on cancer susceptibility, therapy response and prognosis of cancer patients.

Keywords: cancer progression; polymorphisms; tumor biology behaviors; β-adrenergic receptors; β-blockers.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / genetics*
  • Neoplasms / metabolism
  • Polymorphism, Genetic*
  • Receptors, Adrenergic, beta / genetics*
  • Receptors, Adrenergic, beta / physiology
  • Signal Transduction

Substances

  • Adrenergic beta-Antagonists
  • Antineoplastic Agents
  • Receptors, Adrenergic, beta